Novartis' Galvus hits trouble in Germany
This article was originally published in Scrip
Novartis' Galvus (vildagliptin) offers no extra benefit over generic sulfonylureas, according to the G-BA, the body in charge of Germany's tough AMNOG pricing and reimbursement decision. The verdict, part of first ever retrospective assessment looking at drugs that predate the AMNOG system, could lead to a big price cut for the drug, or withdrawal from the market.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.